Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Saturday, January 28, 2012

financial news: AstraZeneca cancels Olaparib trial

"The drugmaker then said that its investigational compound olaparib would not progress into Phase III development for the maintenance treatment of serous ovarian cancer. Additionally, attempts to identify a suitable tablet dose for use in Phase III studies were not successful."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.